menu
    • menu
    [{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Newco Trials Pesquisa Cient\u00edfica Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Dermatology","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Newco Trials Pesquisa Cient\u00edfica Ltda","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Newco Trials Pesquisa Cient\u00edfica Ltda"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Professor Fernando Figueira Integral Medicine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Professor Fernando Figueira Integral Medicine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Professor Fernando Figueira Integral Medicine Institute"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"15","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Hospital Israelita Albert Einstein | University of Sao Paulo","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Dermatology","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Hospital Israelita Albert Einstein | University of Sao Paulo","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Hospital Israelita Albert Einstein | University of Sao Paulo"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Cristalia Produtos Quimicos Farma. Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Amitriptyline","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lodenafil Carbonate","moa":"PDE5 inhibitors","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Santa Casa de S\u00e3o Paulo | Santa Casa de Santos","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Santa Casa de S\u00e3o Paulo | Santa Casa de Santos","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Santa Casa de S\u00e3o Paulo | Santa Casa de Santos"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Newco Trials Pesquisa Cient\u00edfica Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Levobupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Newco Trials Pesquisa Cient\u00edfica Ltda","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Newco Trials Pesquisa Cient\u00edfica Ltda"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Alteogen","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ALT02","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"6","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CRIS100","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Cristalia Produtos Quimicos Farma. Ltda

    Menu

    Cristalia Produtos Quimicos Farma. Ltda

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Recipient : Kashiv BioSciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kashiv and CRISTÁLIA Enter into Licensing and Supply Agreement in Latin America

                            Details : The agreement aims for the commercialization of ADL-018 (Omalizumab), a proposed biosimilar to Xolair, in Latin America (LATAM).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 11, 2025

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Recipient : Kashiv BioSciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formosa Pharmaceuticals Licenses APP13007 for Inflammation and Pain Post-Ocular Surgery

                            Details : Under the agreement, Cristália gets exclusive Brazilian rights for commercializing APP13007 (clobetasol propionate ophthalmic nanosuspension) for inflammation and pain following ocular surgery.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            January 26, 2024

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRIS100

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of CRIS100 on Treatment Spinal Cord Injury

                            Details : CRIS100 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Spinal Cord Injuries.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 22, 2023

                            Lead Product(s) : CRIS100

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyperbaric Novabupi® in Spinal Anesthesia in Lower Limbs Vascular Surgery

                            Details : Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 21, 2019

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)

                            Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhagic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 15, 2018

                            Lead Product(s) : Esmolol Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : University of Sao Paulo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Neuropathic Pain in Leprosy

                            Details : Amitriptyline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neuralgia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2017

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : University of Sao Paulo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT02

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Alteogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects

                            Details : ALT02 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 08, 2017

                            Lead Product(s) : ALT02

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Alteogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Hospital Israelita Albert Einstein | University of Sao Paulo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis

                            Details : Oxybutynin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperhidrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2014

                            Lead Product(s) : Oxybutynin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Hospital Israelita Albert Einstein | University of Sao Paulo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Newco Trials Pesquisa Científica Ltda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.

                            Details : Collagenase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pressure Ulcer.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            December 09, 2013

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Newco Trials Pesquisa Científica Ltda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cristalia Produtos Quimicos Farma. Ltda

                            Brazil arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levobupivacaine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Newco Trials Pesquisa Científica Ltda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III, Evaluate Noninferiority Between Levobupivacaine and Bupivacaine in Spinal Anesthesia.

                            Details : Levobupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Spinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 26, 2013

                            Lead Product(s) : Levobupivacaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Newco Trials Pesquisa Científica Ltda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth